The addition of entheogens or azacitidine to anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death 1 (PD-1) inhibitors significantly inhibited the development of CRC, and the combination therapy was superior to either class of drugs alone [122]. Here, PDCD1 is linked to colorectal carcinoma.